Enterprise Value
158.6M
Cash
9.00K
Avg Qtr Burn
-271.3K
Short % of Float
0.82%
Insider Ownership
28.24%
Institutional Own.
2.02%
Qtr Updated
12/31/22
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
GRI-0621 Details Idiopathic pulmonary fibrosis, Lung disease | Phase 2a Initiation | |
GRI-0803 Details Autoimmune disease, Systemic lupus erythematosus | IND Submission |